Oncology
1 drug is in development for Recurrent Glioblastoma.
- Companies
- 1
- Clinical trials
- 24
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Recurrent Glioblastoma pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 2/Phase 3(1)
| Drug | Company |
|---|---|
| mn-166 | MEDICINOVA INC (MNOV) |
About this indication
Recurrent Glioblastoma context
Oncology·MeSH: Glioblastoma (D005909)
Narrower concept of MeSH descriptor Glioblastoma
Prevalence
3.2 / 100K
Incidence
3.2 / 100K/yr
Frequently asked questions
How many drugs are in development for Recurrent Glioblastoma?
BioSniper tracks 1 drug in development for Recurrent Glioblastoma across 1 company.
How many clinical trials target Recurrent Glioblastoma?
There are 24 clinical trials targeting Recurrent Glioblastoma tracked by BioSniper.
What is the prevalence of Recurrent Glioblastoma?
The estimated prevalence of Recurrent Glioblastoma is approximately 3.2 per 100,000 population.